C-reactive protein as a prognostic factor for human osteosarcoma: A meta-analysis and literature review

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Yi, Jian Hua ^a   Wang, Dong ^a   Li, Zhi Yong ^a   Hu, Jun ^a   Niu, Xiao Feng ^a   Liu, Xiao Lin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BLOOD; META ANALYSIS; METABOLISM;

C-REACTIVE PROTEIN; HUMANS; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84900424234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094632     Document Type: Article

References (107)

1. Gill J, Ahluwalia MK, Geller D, Gorlick R (2013) New targets and approaches in osteosarcoma. Pharmacol Ther 137: 89-99.
2. Sadikovic B, Park PC, Selvarajah S, Zielenska M (2013) Array comparative genomic hybridization in osteosarcoma. Methods Mol Biol 973: 227-247.
3. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84. (Pubitemid 27020560)
4. Ferguson WS, Goorin AM (2001) Current treatment of osteosarcoma. Cancer Invest 19: 292-315. (Pubitemid 32374371)
5. Nakamura T, Grimer RJ, Gaston CL, Watanuki M, Sudo A, et al. (2013) The prognostic value of the serum level of C-reactive protein for the survival of patients with a primary sarcoma of bone. Bone Joint J 95-B: 411-418.
6. Zhu L, McManus MM, Hughes DP (2013) Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol 3: 230.
7. Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, et al. (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer 104: 1100-1109. (Pubitemid 41170240)
8. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, et al. (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577. (Pubitemid 30111481)
9. Dunn D, Dehner LP (1977) Metastatic osteosarcoma to lung: a clinicopathologic study of surgical biopsies and resections. Cancer 40: 3054-3064.
10. Marnell L, Mold C, Du Clos TW (2005) C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117: 104-111. (Pubitemid 41407719)
11. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, et al. (1996) Three dimensional structure of human C-reactive protein. Nat Struct Biol 3: 346-354. (Pubitemid 26112633)
12. Pepys MB (1981) C-reactive protein fifty years on. Lancet 1: 653-657.
13. Volanakis JE (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol 38: 189-197.
14. Deodhar SD (1989) C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 56: 126-130.
15. Devaraj S, Singh U, Jialal I (2009) The evolving role of C-reactive protein in atherothrombosis. Clin Chem 55: 229-238.
16. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454. (Pubitemid 29084777)
17. Heikkila K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61: 824-833.
18. Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44: 6-11. (Pubitemid 38823477)
19. Kushner I, Rzewnicki D, Samols D (2006) What does minor elevation of C-reactive protein signify? Am J Med 119: 166 e117-128.
20. Venugopal SK, Devaraj S, Jialal I (2005) Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 14: 33-37. (Pubitemid 40110697)
21. Wang CS, Sun CF (2009) C-reactive protein and malignancy: clinicopathological association and therapeutic implication. Chang Gung Med J 32: 471-482.
22. Funovics PT, Edelhauser G, Funovics MA, Laux C, Berzaczy D, et al. (2011) Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop 35: 1529-1536.
23. Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250-255.
24. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, et al. (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14: 710-714. (Pubitemid 351231151)
25. Nozoe T, Saeki H, Sugimachi K (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182: 197-201. (Pubitemid 32907362)
26. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375: 1267-1277.
27. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
28. Cota GF, de Sousa MR, Fereguetti TO, Rabello A (2013) Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195.
29. Lyu YX, Yu XC, Zhu MY (2013) Comparison of the diagnostic value of procalcitonin and C-reactive protein after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transpl Infect Dis 15: 290-299.
30. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
31. Terlizzi M, Casolaro V, Pinto A, Sorrentino R (2014) Inflammasome: Cancer's friend or foe? Pharmacol Ther.
32. Smith GR, Missailidis S (2004) Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 1: 3.
33. Schwartsburd PM (2003) Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 22: 95-102.
34. Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, et al. (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82: 846-851.
35. de Martino M, Klatte T, Seemann C, Waldert M, Haitel A, et al. (2013) Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 111: E348-353.
36. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, et al. (2012) Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 12: 399.
37. Ito K, Yoshii H, Sato A, Kuroda K, Asakuma J, et al. (2011) Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 186: 430-435.
38. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, et al. (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55: 1145-1153.
39. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, et al. (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247. (Pubitemid 47435594)
40. Komai Y, Saito K, Sakai K, Morimoto S (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99: 77-80. (Pubitemid 44915624)
41. Eggers H, Seidel C, Schrader AJ, Lehmann R, Wegener G, et al. (2013) Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 30: 705.
42. Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, et al. (2012) Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int 110: 1478-1484.
43. Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, et al. (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 108: 1800-1805.
44. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, et al. (2008) C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 101: 978-981. (Pubitemid 351422558)
45. Han Y, Mao F, Wu Y, Fu X, Zhu X, et al. (2011) Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers 26: 209-215.
46. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE (2011) Elevated pretreatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 13: R55.
47. Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, et al. (1995) Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 21: 504-509.
48. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, et al. (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94: 227-230. (Pubitemid 43151540)
49. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444.
50. Alkhateeb AA, Leitzel K, Ali SM, Campbell-Baird C, Evans M, et al. (2012) Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. Plos one 7: e51379.
51. Mohri Y, Tanaka K, Ohi M, Toiyama Y, Yasuda H, et al. (2012) Inflammation-based prognostic score as a predictor of postoperative gastric cancer recurrence. Anticancer Res 32: 4581-4584.
52. Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, et al. (2012) C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res 32: 491-496.
53. Woo Y, Hyung WJ, Obama K, Kim HI, Pak KH, et al. (2012) Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol 105: 405-409.
54. Nozoe T, Iguchi T, Adachi E, Matsukuma A, Ezaki T (2011) Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today 41: 510-513.
55. Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N (2004) Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 48: 171-173. (Pubitemid 39045778)
56. Toiyama Y, Fujikawa H, Koike Y, Saigusa S, Inoue Y, et al. (2013) Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncol Lett 5: 1881-1888.
57. Takasu C, Shimada M, Kurita N, Iwata T, Nishioka M, et al. (2013) Impact of C-reactive protein on prognosis of patients with colorectal carcinoma. Hepatogastroenterology 60: 507-511.
58. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, et al. (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98: 540-544.
59. Nozoe T, Mori E, Takahashi I, Ezaki T (2008) Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today 38: 597-602. (Pubitemid 351977653)
60. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, et al. (2007) C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 96: 222-225. (Pubitemid 46160625)
61. Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369-373.
62. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R (2009) Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 45: 912-914.
63. Zeng YC, Xue M, Chi F, Xu ZG, Fan GL, et al. (2012) C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Tumour Biol 33: 891-895.
64. Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, et al. (2011) Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol 36: 147-153.
65. Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang HW, et al. (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92: 270-275.
66. Gockel I, Dirksen K, Messow CM, Junginger T (2006) Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12: 3746-3750. (Pubitemid 43950953)
67. Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18: 146-150. (Pubitemid 41801107)
68. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, et al. (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248-252. (Pubitemid 36936011)
69. Feng JF, Zhao HG, Liu JS, Chen QX (2013) Significance of preoperative C-reactive protein as a parameter in patients with small cell carcinoma of the esophagus. Onco Targets Ther 6: 1147-1151.
70. Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, et al. (2012) Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int 110: E461-468.
71. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, et al. (2011) Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 78: 1131-1135.
72. McCall P, Catlow J, McArdle PA, McMillan DC, Edwards J (2011) Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomark 10: 91-99.
73. Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, et al. (2012) C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 30: 33-37.
74. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, et al. (2008) C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112: 2377-2383.
75. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T (2012) Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 32: 3535-3538.
76. Hong S, Kang YA, Cho BC, Kim DJ (2012) Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 53: 111-117.
77. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R (2010) Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 5: 988-992.
78. Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, et al. (2010) Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 102: 1113-1122.
79. Koch A, Fohlin H, Sorenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4: 326-332.
80. Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, et al. (2012) Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13: 199-204.
81. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, et al. (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35: 605-610.
82. Andersson BA, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, et al. (2014) Plasma tumor necrosis factor-alpha and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 140: 515-519.
83. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, et al. (2013) Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer.
84. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, et al. (2012) Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer 118: 1055-1061.
85. Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, et al. (2003) Diagnostic implications of C-reactive protein. Arch Surg 138: 220-224. (Pubitemid 36216291)
86. Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH, Jr. (2000) Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 68: 5652-5656.
87. Szalai AJ, Briles DE, Volanakis JE (1995) Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 155: 2557-2563.
88. Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-170.
89. Hribal ML, Fiorentino TV, Sesti G (2013) Role of C Reactive Protein (CRP) in Leptin Resistance. Curr Pharm Des.
90. Choi J, Joseph L, Pilote L (2013) Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14: 232-244.
91. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR (2012) Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 1825: 207-222.
92. Cha-Molstad H, Young DP, Kushner I, Samols D (2007) The interaction of C-Rel with C/EBPbeta enhances C/EBPbeta binding to the C-reactive protein gene promoter. Mol Immunol 44: 2933-2942. (Pubitemid 46412491)
93. Zhang D, Sun M, Samols D, Kushner I (1996) STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 271: 9503-9509. (Pubitemid 26139927)
94. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I (2000) The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 165: 4592-4597.
95. Voleti B, Agrawal A (2005) Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol 175: 3386-3390. (Pubitemid 41170561)
96. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, et al. (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180: 3492-3501.
97. Das T, Sen AK, Kempf T, Pramanik SR, Mandal C (2003) Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J 373: 345-355. (Pubitemid 36897838)
98. Mulrooney DA, Ness KK, Huang S, Solovey A, Hebbel RP, et al. (2013) Pilot study of vascular health in survivors of osteosarcoma. Pediatr Blood Cancer 60: 1703-1708.
99. Peng TI, Hsiao CW, Reiter RJ, Tanaka M, Lai YK, et al. (2012) mtDNA T8993G mutation-induced mitochondrial complex V inhibition augments cardiolipin-dependent alterations in mitochondrial dynamics during oxidative, Ca(2+), and lipid insults in NARP cybrids: a potential therapeutic target for melatonin. J Pineal Res 52: 93-106.
100. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, et al. (2011) Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 179: 1157-1170.
101. Jansson AF, Muller TH, Gliera L, Ankerst DP, Wintergerst U, et al. (2009) Clinical score for nonbacterial osteitis in children and adults. Arthritis Rheum 60: 1152-1159.
102. Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, et al. (2005) Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 16: 1199-1206. (Pubitemid 41418325)
103. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, et al. (2005) Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A 102: 3423-3428. (Pubitemid 40328061)
104. Trapani S, Grisolia F, Simonini G, Calabri GB, Falcini F (2000) Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum 29: 348-359. (Pubitemid 30413822)
105. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, et al. (1995) Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 17: 181-193.
106. Asano T, Kleinerman ES (1993) Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol 14: 286-292. (Pubitemid 23322747)
107. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, et al. (1992) Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 10: 1310-1316.